Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study

• DOI: 10.1007/s15010-022-01914-8
• Publication Date: 2022-09-09T12:37:36Z
• Authors: Nikolaus Kneidinger; Matthias Hecker; Vasiliki Bessa; Ina Hettich; Alexandra Wald; Sabine Wege; Anna-Barbara Nolde; Maike Oldigs; Zulfiya Syunyaeva; Heinrike Wilkens; Jens Gottlieb
• Keywords: Interquartile range; Renal replacement therapy

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients Omicron era remains unknown. aim study was to assess outcome and associated factors a German-wide multicenter approach. All affected individuals from January 1st March 20th, 2022 8 German centers during wave were collected. Baseline characteristics antiviral measures with outcome. Of 218 patients PCR-proven SARS-CoV-2 infection 166 (76%) received any early (< 7 days) therapy median (interquartile range 1-4) days after symptom onset. Most sotrovimab (57%), followed remdesivir (21%) molnupiravir (21%). An combination applied 45 Thirty-four (16%) developed or critical severity according WHO scale. In total, 14 (6.4%) died subsequently COVID-19. Neither vaccination antibody status, nor treatments Only age glomerular filtration rate < 30 ml/min/1.73m2 independent risk due an important recipients. particular, elderly impaired kidney function are at worse Prophylaxis highly need further improvement.